Teva CEO Schultz Walks Smack Into A Rough Financial Situation
Executive Summary
Teva announced lower third quarter sales, said it would miss it's 2017 profit forecasts and acknowledged looming debt challenges. It was only CEO Kare Schultz's second day on the job.
You may also be interested in...
Teva: No Reason To "Panic" When It Comes To Ajovy Access
Discussions with payers for market access for the migraine drug will continue through November and into December. The level of rebating in the category will be around 25%, management forecast.
Teva: No Reason To "Panic" When It Comes To Ajovy Access
Discussions with payers for market access for the migraine drug will continue through November and into December. The level of rebating in the category will be around 25%, management forecast.
Sandoz's Less Frequently Dosed Copaxone Generic Glatopa Hits Teva Two Months Early
Teva said its 2018 revenue guidance reflected an April launch for the 40 mg dose of Glatopa, but Sandoz and partner Momenta announced FDA approval and the US launch of their less frequently administered Copaxone generic on Feb. 13.
Need a specific report? 1000+ reports available
Buy Reports